Clinical Study On Different Dose Statin Treating Acute Cerebral Infarction

Objective To investigate the effects of statin in different dose in endothelial progenitor cells(EPCs),high sensitivity C reactive protein(hsCRP)levels and the neurological impairment in patients with acute cerebral infarction(ACI),so as to explore the benefits of high dose of statin on ACI.Methods Forty-two patients with ACI were involved in present study,and they were randomly divided into two groups.rosuvastatin 10 mg and 20 mg group.Lipids contents were determined respectively before and 21 days after the treatment.EPCs were marked as CD45dimCD34+/CD133+/KDR+ cells by cytometry detection.Before treatment and 7,14,and 21 days after the treatment,the numbers of EPCs and the plasma levels of hsCRP were determined respectively.The plasma levels of hsCRP were tested with ELISA.The NIH Stroke scale(NIHSS)score were determined respectively before treatment and 7,14,21 and 30 days after the treatment.Results 1.After treatment,Total cholesterol(TC),triglyceride(TG)and low density lipoprotein cholesterol(LDL-C)lowered and high density lipoprotein cholesterol(HDL-C)rose obviously with significant difference(P<0.05)in two groups.TC and LDL-C lowered in a dose-dependent manner.2.The number of EPCs increased with significant difference(P<0.05),they changed in a dose-dependent manner at 14 and 21 days after the treatment.3.The level of hsCRP were decreased with significant difference(P<0.05),they changed in a dose-dependent manner 7,14 and 21 days after treatment.4.After 30 days of treatment,NIHSS scores were decreased with significant difference(P<0.05)between 10 mg and 20 mg rosuvastain group.5.During 72 h onset of ACI,the NIHSS score had negative correlation with peripheral EPCs(r=-0.413,P=0.007),the NIHSS score had positive correction with the plasma levels of hsCRP(r=0.556,P=0.000),and the NIHSS score had negative correlation with peripheral EPCs(r=-0.472,P=0.002)Conclusion Our findings show that 20 mg rosuvastain safely and effectly reduce the blood lipid levels,hsCRP levels,increase the number of EPCs,and reduce NIHSS scores to some extent.However,further large sample study should be untaken to determine if the long-term and high-dose statin is safe and effective for ACI.